Skip to main content
    I

    Ideaya Biosciences Inc (IDYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $30.36
    -1.47 (-4.62%)

    Market Cap: $3.08B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ideaya Biosciences Inc (IDYA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Ideaya Biosciences reported revenue of $218.71M for the fiscal year ended Dec 31, 2025, up 3024.4% from the year before. That year, net income was -$113.70M with a net margin of -52.0%, operating cash flow was -$71.10M and free cash flow was -$73.47M. The quarter ended Sep 30, 2026 had revenue of $10.24M and net income of -$125.75M.

    Revenue and Margins

    The operating margin was -72.8% in the fiscal year ended Dec 2025. Over the 5 years to Dec 2025, revenue grew from $19.54M, a compound annual rate of 62.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$218.71M+3024.4%100.0%-72.8%-52.0%
    Dec 2024$7.00M-70.1%100.0%-4671.1%-3921.1%
    Dec 2023$23.39M-54.1%100.0%-574.9%-483.0%
    Dec 2022$50.93M+82.3%100.0%-122.7%-115.2%
    Dec 2021$27.94M+43.0%100.0%-179.9%-178.1%
    Dec 2020$19.54MN/A100.0%-180.9%-176.6%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$218.71M$7.00M$23.39M$50.93M$27.94M$19.54M$0$0$0
    Cost of revenue$0$0$0$0$0$0$0$0$391.00K
    Gross profit$218.71M$7.00M$23.39M$50.93M$27.94M$19.54M$0$0-$391.00K
    Research and development$314.70M$294.67M$129.51M$89.54M$58.16M$39.70M$34.32M$31.75M$12.38M
    Operating income-$159.31M-$326.98M-$134.43M-$62.50M-$50.27M-$35.34M-$44.27M-$36.42M-$14.44M
    Net income-$113.70M-$274.48M-$112.96M-$58.66M-$49.76M-$34.49M-$41.98M-$34.35M-$11.86M
    EBITDA-$119.08M-$293.88M-$120.51M-$59.68M-$44.90M-$33.38M-$43.50M-$36.34M-$11.47M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$10.24M$8.86M$6.56M$10.88M$207.83M$0$0$7.00M$0$0$0$3.92M
    Gross profit$10.24M$8.86M$6.56M$10.88M$207.83M$0$0$7.00M$0$0$0$3.92M
    Operating income-$137.63M-$122.29M-$108.54M-$94.57M$108.45M-$88.81M-$84.39M-$144.14M-$66.89M-$64.93M-$51.02M-$41.91M
    Net income-$125.75M-$112.45M-$98.54M-$83.27M$119.24M-$77.49M-$72.18M-$130.31M-$51.82M-$52.77M-$39.57M-$33.95M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $339.00K by $112.49M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$1.11B$1.12B$649.32M$387.97M$381.35M$298.27M$113.00M$96.54M$17.48M
    Current assets$666.73M$689.71M$532.63M$370.45M$251.00M$288.61M$101.65M$90.67M$13.58M
    Cash and equivalents$112.83M$84.38M$157.02M$68.63M$92.05M$72.04M$34.07M$20.50M$5.96M
    Total liabilities$86.39M$64.94M$28.23M$38.51M$79.83M$100.00M$12.60M$7.10M$33.22M
    Short-term debt$339.00K$298.00K$1.75M$1.87M$1.70M$1.54M$1.15M$0$0
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$0$3.21M
    Shareholder equity$1.02B$1.06B$621.09M$349.45M$301.51M$198.27M$100.40M-$48.95M-$15.74M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.22B$1.31B$1.03B$1.11B$1.19B$1.04B$1.10B$1.12B$1.24B$973.66M$961.53M$649.32M
    Total liabilities$123.96M$110.79M$93.08M$86.39M$93.10M$81.62M$76.51M$64.94M$59.45M$42.01M$26.22M$28.23M
    Cash and equivalents$261.45M$272.59M$157.52M$112.83M$298.93M$114.64M$130.00M$84.38M$400.28M$183.05M$108.34M$157.02M
    Shareholder equity$1.09B$1.20B$937.27M$1.02B$1.09B$959.65M$1.02B$1.06B$1.18B$931.66M$935.31M$621.09M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$71.10M-$247.58M-$115.22M-$87.17M-$55.78M$55.46M-$39.31M-$27.62M-$12.22M
    Capital expenditures$2.37M$3.86M$2.37M$3.44M$2.64M$493.00K$1.35M$1.71M$1.76M
    Free cash flow-$73.47M-$251.44M-$117.59M-$90.62M-$58.42M$54.97M-$40.67M-$29.33M-$13.98M
    Investing cash flow$69.98M-$502.56M-$158.46M-$33.40M-$69.67M-$146.24M$2.27M-$63.18M-$8.93M
    Financing cash flow$29.78M$677.55M$362.72M$97.17M$145.45M$128.75M$50.61M$105.38M$17.49M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$93.48M-$88.21M-$75.17M-$90.50M$142.21M-$62.47M-$60.34M-$121.66M-$49.23M-$32.88M-$43.81M-$23.75M
    Capital expenditures$273.00K$866.00K$967.00K$333.00K$42.00K$663.00K$1.33M$1.10M$457.00K$973.00K$1.32M$838.00K
    Free cash flow-$93.75M-$89.08M-$76.14M-$90.83M$142.17M-$63.14M-$61.67M-$122.76M-$49.69M-$33.85M-$45.14M-$24.59M
    Last 12 quarters

    Frequently Asked Questions About IDYA

    What is Ideaya Biosciences' annual revenue?

    Ideaya Biosciences reported revenue of $218.71M for the fiscal year ended Dec 31, 2025.

    How fast is Ideaya Biosciences' revenue growing?

    Revenue was up 3024.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 62.5%.

    Is Ideaya Biosciences profitable?

    No. Ideaya Biosciences reported net income of -$113.70M for the fiscal year ended Dec 31, 2025, with a net margin of -52.0%.

    How much free cash flow does IDYA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$71.10M minus capital expenditures of $2.37M produced free cash flow of -$73.47M.

    How much debt does Ideaya Biosciences have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $339.00K and cash and equivalents of $112.83M.